Modelled impact of antiviral therapy on the future burden of HCV disease in Scotland Testing/Treatment/Care Working Group, 11 th Sept 2007.

Slides:



Advertisements
Similar presentations
Institute for Public Health, Medical Decision Making and Health Technology Assessment 1 Results of the PanEuropean Hepatitis C Project 3 rd Paris Hepatitis.
Advertisements

Hcv infection and management in advanced liver disease
The effect of improved HCV diagnosis and treatment on public health The effect of improved HCV diagnosis and treatment on public health P Mathurin Hôpital.
Hepatitis web study Hepatitis web study Sofosbuvir in HCV Genotype 2, 3 (PEG not an Option) POSITRON Phase 3 *Note: Published in tandem with FUSION Trial.
Management of Hepatitis C in Alcohol and Other Drug Services Greg Dore Viral Hepatitis Clinical Research Program National Centre in HIV Epidemiology and.
The new Treatments Dr John F Dillon. Curing one person Curing a population one person at a time.
Liver Disease and Thalassaemia George Constantinou.
N ORTHWEST AIDS E DUCATION AND T RAINING C ENTER CROI 2015: What’s New in Hepatitis? Nina Kim, MD Associate Professor of Medicine Division of Allergy &
Hepatitis web study Hepatitis web study Sofosbuvir + Peginterferon + Ribavirin in Genotypes 1,4,5,6 ATOMIC Phase 2 Treatment Naïve Kowdley K, et al. Lancet.
Treatment of HCV infection among active IDUs Jason Grebely, PhD Lecturer Viral Hepatitis Clinical Research Program National Centre in HIV Epidemiology.
Hepatitis web study H EPATITIS W EB S TUDY Christian B. Ramers, MD, MPH Assistant Medical Director, Family Health Centers of San Diego HIV/HCV Distance.
Module 6: Treatment options. Module goal To enable participants understand the best current treatment options, factors that influence outcomes and potential.
Cost-Effectiveness of a One-Time National Hepatitis C Screening Program: Impact of a Selective Drug Reimbursement Policy CADTH Symposium April 14, 2015.
Hepatitis C Virus Infection Hepatitis C Virus Infection Burden of Disease in United States New infections (cases)/year , ,000 Persons.
Division of Viral Hepatitis
Abstract Results Objectives Results Conclusions Background Methods V-1637 Background-At the CORE center in Chicago, despite an on-site hepatitis clinic.
This is the most comprehensive compilation of epidemiological information on Hepatitis C Graciously provided by the University Hepatitis Center (last updated.
Liver fibrosis regression after anti HCV therapy and the rate of death, liver-related death, liver- related complications, and hospital.
NICE Guidelines on the Use of Ribavirin and Interferon Alpha for Hepatitis C Matt Johnson and Dr. Hunt / Asante / Jenkins.
Management of Chronic HCV Infection by PMDs Rod Rahimi Osler Journal Club
Hepatitis C, Drug Use and Stigma Liz Allen. What it is Hepatitis C? Hepatitis C is a blood-borne virus Can cause serious damage to the liver First indentified.
Hepatitis C: The Next Tsunami Danny Jenkins Cri-Help Common Ground – The Westside HIV Community Center We Write the Grants
HEPATITIS C VIRUS REINFECTION IN PEOPLE WHO INJECT DRUG (PWID) PREVIOUSLY SUCCESFULY TREATED G. Ntetskas, V. Papastergiou, L. Skorda, A. Katsili, E. Anastasiou,
Tackling hepatitis C - what PHE modelling shows us Helen Harris BSc PhD FFPH LJWG meeting; November 2014.
Hepatitis web study H EPATITIS W EB S TUDY H EPATITIS C O NLINE Treatment of Chronic HCV Genotype 5 or 6 Robert G. Gish MD Staff Physician, Stanford University.
The Swiss Population In 2001 Resident population: 7,258,500 Population density: 176 per Km 2 Foreign nationals: 20.1% (~1,460,000) Excess of births over.
Department of SOCIAL MEDICINE University of BRISTOL The primary prevention of hepatitis C among injectors: model projections of the impact of opiate substitution.
How aspirations can be built and levels of performance can be assured: Learning from the Scottish Action Plan Professor Sharon Hutchinson LJWG LDAPF Conference.
Hepatitis C Needs Assessment: Contributions from the National HCV Diagnosis and Local Clinical Databases.
HEPATITIS C Kimberly Klatt. CHARACTERISTICS  Virus  Enveloped  Single-stranded RNA virus  High mutation rate  6 different genotypes  Most cases.
Hepatitis C: Perspective on Drug Development Issues Debra Birnkrant, M.D. Director, Division of Antiviral Products FDA Antiviral Drugs Advisory Committee.
STATINS ARE ASSOCIATED WITH A DECREASED RISK OF DECOMPENSATION AND DEATH IN VETERANS WITH HEPATITIS C-RELATED COMPENSATED CIRRHOSIS PREPARED BY PAULINA.
Alcohol Drugs and Hepatitis C, Brewing up a perfect storm COSLA Haymarket, Edinburgh 24 June 2015 Epidemiological overview Professor David Goldberg, Health.
Trends in Treatment of Recurrent Hepatitis C After Liver Transplantation Kate Forgan-Smith KA Stuart 1,4, C Tallis 1,4 GA Macdonald 1,3,4, J Fawcett 2,3.
Date of download: 6/1/2016 From: Cost-Effectiveness of Novel Regimens for the Treatment of Hepatitis C Virus Ann Intern Med. 2015;162(6): doi: /M
Date of download: 6/1/2016 From: Prevention of Hepatitis C by Screening and Treatment in U.S. Prisons Ann Intern Med. 2016;164(2): doi: /M
Liver transplantation for HCV infection R3 양 인 호 /Prof 김 병 호.
Date of download: 6/2/2016 From: New Protease Inhibitors for the Treatment of Chronic Hepatitis C: A Cost-Effectiveness Analysis Ann Intern Med. 2012;156(4):
Baby Boomer Screening Targets the Most Vulnerable to HCV Morbidity and Mortality 73% of HCV-related deaths are in this cohort. A one-time-only hepatitis.
What is the contribution of alcohol to liver disease in the hepatitis C infected population. The epidemiological evidence Hamish Innes Research Fellow.
Setting the Scene. Non A, non B Hepatitis  Early 1970’s recognised that 2/3 of post transfusional hepatitis were –ve for both Hep A & Hep B Non Hep A.
HBV. Overview of the Epidemiology of Hepatotropic Viruses.
Template ID: junglegreens Size: 36x48 Impact of Hepatitis C Screening in Outpatient Population Madhuri Chandnani MD, Pallavi Pothuri MD, Michael Stevens.
Date of download: 9/17/2016 From: The Changing Burden of Hepatitis C Virus Infection in the United States: Model-Based Predictions Ann Intern Med. 2014;161(3):
Economic Impact of Eliminating HCV H. Razavi April 13, 2016.
Addressing Viral Hepatitis
Viral Hepatitis Graham R Foster Professor of Hepatology
Phase 3 Treatment-Naïve and Treatment-Experienced
Achieving WHO Recommendations for HCV in the European Union
Projected global distribution of total deaths (58 million) by major cause, 2005 Kathleen Strong et al, Lancet 2005; 366: 1578–82.
Interactive Workshop.
Achieving WHO Recommendations for HCV Elimination in the Eastern Mediterranean Region I. Waked April 12, 2016.
HCV & liver transplantation
Eradication of HCV induced by DAAs
A. Stepanov, A. Kruk, N. Polovinkina, A. Vinogradova
Volume 143, Issue 4, Pages e14 (October 2012)
Talking to Patients About HCV Treatment
Starting Strong: Initial Evaluation of the Patient With HCV
Achieving WHO Recommendations for HCV Elimination in the Western Pacific Region L. Wei April 13, 2016.
HCV Care in Unique Patient Populations
Risk of de novo Hepatocellular Carcinoma after HCV Treatment with Direct-Acting Antivirals Liver Cancer - DOI: / Fig. 1. Flowchart of included.
New Agents, New Regimens, New Strategies
Volume 153, Issue 4, Pages (October 2017)
Cost-Effectiveness Analysis of New HCV Treatments in Egyptian Cirrhotic and Non- Cirrhotic Patients: A Societal Perspective  Gihan Hamdy Elsisi, MSc, PhD,
A Sustained Viral Response Is Associated With Reduced Liver-Related Morbidity and Mortality in Patients With Hepatitis C Virus  Amit G. Singal, Michael.
Volume 61, Issue 3, Pages (September 2014)
Volume 138, Issue 2, Pages e6 (February 2010)
Hepatitis C treatment in patients with kidney disease
Robert G. Gish, Nezam H. Afdhal, Douglas T. Dieterich, K
Reversion of disease manifestations after HCV eradication
Presentation transcript:

Modelled impact of antiviral therapy on the future burden of HCV disease in Scotland Testing/Treatment/Care Working Group, 11 th Sept 2007

Effectiveness and cost-effectiveness of HCV antiviral therapy Overall response rates of 50-60% with antiviral therapy Overall response rates of 50-60% with antiviral therapy Cost-effectiveness studies have demonstrated that antiviral therapy leads to gains in QALYs that justify the additional cost of treatment Cost-effectiveness studies have demonstrated that antiviral therapy leads to gains in QALYs that justify the additional cost of treatment NICE & QIS recommend pegylated interferon plus ribavirin for patients with mild and moderate disease & compensated cirrhosis NICE & QIS recommend pegylated interferon plus ribavirin for patients with mild and moderate disease & compensated cirrhosis

Burden of HCV disease among IDUs in Scotland, 2008 Chronic Infection Mild disease Moderate disease Severe disease (cirrhosis) No infection Liver failure HCV All IDUsFormer IDUs 35,70028,400 21,80015,700 11,90010,800 2,000 1, per year Hutchinson et al. Hepatology 2005

Modelled prevalent number of HCV infected IDUs in Scotland according to stage of HCV disease, Living IDUs (thousands) 2008 Calendar year Mild disease Moderate disease Cirrhosis Recovered from HCV Cleared HCV from treatment Hutchinson et al. Hepatology 2005

Cirrhosis prevented from antiviral therapy* Living IDUs with cirrhosis ,000 2,000 3, ,000 2,000 3, ,000 2,000 3,000 Decompensated cirrhosis HCC * Excludes those prevented from antiviral therapy prior to 2008 Compensated cirrhosis Modelled number of IDUs with cirrhosis in Scotland by different uptake rates of HCV antiviral therapy, Uptake of therapy by 225 IDUs per year Uptake of therapy by 1,000 IDUs per year Uptake of therapy by (up to) 2,000 IDUs per year

Annual number of IDUs developing liver failure Cumulative number of liver failures prevented from therapy Modelled number of IDUs in Scotland with liver failure with different uptake rates of HCV antiviral therapy, Assuming uptake of HCV antiviral therapy by: Annual number ,000 Cumulative number 0 former IDUs per year 0 former IDUs per year 225 former IDUs per year 225 former IDUs per year 1,000 former IDUs per year (up to) 2,000 former IDUs per year

Cohort members (living/dead) ,000 20,000 30,000 Modelled follow-up of 35,000 IDUs in Scotland with chronic HCV disease (mild/moderate/compensated cirrhosis) in 2008 Scenario for entire IDU population: Uptake of therapy by 225 IDUs per year Cleared HCV from antiviral therapy Mild disease Moderate disease Cirrhosis HCV-related death Non-HCV-relateddeath

Cohort members (living/dead) ,000 20,000 30,000 Modelled follow-up of 35,000 IDUs in Scotland with chronic HCV disease (mild/moderate/compensated cirrhosis) in 2008 Cleared HCV from antiviral therapy Mild disease Moderate disease Cirrhosis HCV-related death Non-HCV-relateddeath In 2030, 7% of 19,500 living cohort members estimated to have cleared HCV from antiviral therapy Scenario for entire IDU population: Uptake of therapy by 225 IDUs per year

Cohort members (living/dead) ,000 20,000 30, ,000 20,000 30,000 Modelled follow-up of 35,000 IDUs in Scotland with chronic HCV disease (mild/moderate/compensated cirrhosis) in 2008 Uptake of therapy by 1,000 IDUs per year Uptake of therapy by (up to) 2,000 IDUs per year 31% of the 19,800 alive cleared HCV from antiviral therapy 50% of the 20,100 alive cleared HCV from antiviral therapy

Cohort members (living/dead) ,000 20,000 30,000 Modelled follow-up of 35,000 IDUs in Scotland with chronic HCV disease (mild/moderate/compensated cirrhosis) in 2008 Cleared HCV from antiviral therapy Mild disease Moderate disease Cirrhosis HCV-related death Non-HCV-relateddeath  16% died from HCV-related cause during  260 HCV-related deaths averted from antiviral therapy Scenario for entire IDU population: Uptake of therapy by 225 IDUs per year

Cohort members (living/dead) ,000 20,000 30, ,000 20,000 30,000 Modelled follow-up of 35,000 IDUs in Scotland with chronic HCV disease (mild/moderate/compensated cirrhosis) in 2008 Uptake of therapy by 1,000 IDUs per year Uptake of therapy by (up to) 2,000 IDUs per year  13% died from HCV-related cause  1,250 HCV-related deaths averted  11% died from HCV-related cause  2,000 HCV-related deaths averted

Health service costs & quality of life (QOL) associated with stages of chronic HCV disease, 2005 StageAnnual cost per patientQOL Mild diseaseUndiagnosed Diagnosed During therapy SVR £0 £144 ** Moderate diseaseUndiagnosed Diagnosed During therapy SVR £0 £749 ** Compensated cirrhosis Undiagnosed Diagnosed During therapy SVR £0 £1,188 ** Decompensated cirrhosis£9, HCC£8, Liver TransplantTransplant costs 1 st yr follow-up 2 nd yr follow-up £28,533 £9,874 £1, Treatment costs (Peg Interferon & Rib therapy & monitoring costs) £8,781**-

Cost-effectiveness analysis of increasing uptake of HCV antiviral therapy in Scotland Entire IDU population IDU cohort: Cumulative cost* ( ) Uptake of antiviral therapy by former IDUs Management/ Monitoring of HCV disease HCV antiviral therapy Total N per year Cumulative number during (% of 35,000) 00 £276 million £0 £0 £276 million ,100 (15%) 5,100 (15%) £263 million £26 million £289 million 1,000 21,300 (61%) £220 million £112 million £332 million 2,000 29,100 (83%) £185 million £177 million £362 million * Discounted at 3.5%

Cost-effectiveness analysis of increasing uptake of HCV antiviral therapy in Scotland Entire IDU population IDU cohort: Incremental Cost* ( ) Incremental gain in QALYS* ( )Incremental Cost Effectiveness Ratio** (£/ QALY) Uptake of antiviral therapy by former IDUs N per year Cumulative number during (% of 35,000) ,100 (15%) 5,100 (15%) £13 million 1,700£7,800 1,000 21,300 (61%) £43 million 5,800£7,500 2,000 29,100 (83%) £30 million 5,800£5,100 * Discounted at 3.5% ** Defined as additional cost per additional gain in quality adjusted life year (QALY) for a given scenario compared to the next less effective scenario (QALY) for a given scenario compared to the next less effective scenario

Current uptake of antiviral therapy will have limited impact on severe HCV-related liver disease in the future Current uptake of antiviral therapy will have limited impact on severe HCV-related liver disease in the future Uptake of therapy by 1,000-2,000 persons per year will potentially prevent 500-1,000 liver failures during Uptake of therapy by 1,000-2,000 persons per year will potentially prevent 500-1,000 liver failures during Increasing uptake of HCV antiviral therapy in Scotland to 1,000-2,000 persons per year leads to gains in QALYs that justify the additional cost of treatment Increasing uptake of HCV antiviral therapy in Scotland to 1,000-2,000 persons per year leads to gains in QALYs that justify the additional cost of treatment Summary Results